Cassava Sciences Inc vs Nerdwallet Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Nerdwallet Inc trades at $9.59 (market cap $627.06M). The key difference: Nerdwallet Inc is far larger — about 11.8× Cassava Sciences Inc's market cap, and Nerdwallet Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | NRDS | |
|---|---|---|
Market Cap | $53.14M | $627.06M |
Sector | Health | Financials |
52-Week High | $4.64 | $15.93 |
52-Week Low | $1.09 | $7.58 |
Enterprise Value | -$33.43M | $541.36M |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
NerdWallet (NRDS) trades at $9.47, showing modest daily gains. The stock presents a mixed technical picture with a bearish overall signal but strong fundamental metrics, including a low P/E of 10.25, a high gross margin of 93.04%, and consistent earnings beats. Recent quarterly results have exceeded expectations, and analyst consensus is bullish with a $12.75 price target, implying significant upside.
The outlook is positive due to attractive valuation, strong profitability, and a successful business pivot. Key risks include a bearish technical trend, potential revenue headwinds from declining search traffic, and execution challenges in sustaining high growth. The stock offers a compelling risk-reward profile for value-oriented investors seeking exposure to financial services.
Trailing returns across standard periods
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →